Jafron Common Stock Shares Outstanding vs Total Assets Analysis

300529 Stock   30.48  0.41  1.36%   
Jafron Biomedical financial indicator trend analysis is infinitely more than just investigating Jafron Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jafron Biomedical is a good investment. Please check the relationship between Jafron Biomedical Common Stock Shares Outstanding and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Common Stock Shares Outstanding vs Total Assets

Common Stock Shares Outstanding vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jafron Biomedical Common Stock Shares Outstanding account and Total Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between Jafron Biomedical's Common Stock Shares Outstanding and Total Assets is 0.68. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Assets in the same time period over historical financial statements of Jafron Biomedical Co, assuming nothing else is changed. The correlation between historical values of Jafron Biomedical's Common Stock Shares Outstanding and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Jafron Biomedical Co are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Common Stock Shares Outstanding i.e., Jafron Biomedical's Common Stock Shares Outstanding and Total Assets go up and down completely randomly.

Correlation Coefficient

0.68
Relationship DirectionPositive 
Relationship StrengthSignificant

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Jafron Biomedical assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Jafron Biomedical books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Jafron Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
The current year's Tax Provision is expected to grow to about 119.8 M, whereas Selling General Administrative is forecasted to decline to about 363.6 M.
 2021 2022 2023 2024 (projected)
Operating Income1.4B1.0B523.2M528.6M
Total Revenue2.7B2.5B1.9B1.2B

Jafron Biomedical fundamental ratios Correlations

-0.030.960.890.970.890.951.00.980.710.950.610.940.880.950.990.490.920.970.950.950.870.810.910.680.94
-0.03-0.130.24-0.10.2-0.270.00.020.47-0.310.42-0.280.140.05-0.040.660.15-0.180.07-0.050.340.45-0.35-0.28-0.16
0.96-0.130.780.950.760.980.960.960.510.980.40.970.770.90.950.320.820.930.870.890.790.770.920.740.88
0.890.240.780.820.990.750.880.840.860.740.760.710.960.870.880.740.980.820.970.930.890.880.660.30.89
0.97-0.10.950.820.830.940.970.970.650.950.520.960.820.920.980.380.850.960.90.910.840.740.940.70.92
0.890.20.760.990.830.740.870.850.850.750.80.730.980.850.880.720.980.850.970.950.890.850.690.310.92
0.95-0.270.980.750.940.740.940.920.480.990.370.970.760.890.940.250.80.930.850.890.730.680.940.740.89
1.00.00.960.880.970.870.940.980.690.950.580.940.860.940.990.470.910.960.940.930.870.820.90.690.92
0.980.020.960.840.970.850.920.980.680.930.550.950.840.890.960.470.880.950.920.920.910.830.920.680.91
0.710.470.510.860.650.850.480.690.680.470.860.470.780.70.690.850.770.610.780.690.860.710.430.240.67
0.95-0.310.980.740.950.750.990.950.930.470.380.990.760.870.940.230.80.960.860.890.730.660.970.750.91
0.610.420.40.760.520.80.370.580.550.860.380.380.780.650.630.770.70.590.660.620.670.580.350.220.61
0.94-0.280.970.710.960.730.970.940.950.470.990.380.740.860.940.20.780.960.850.880.750.650.990.760.9
0.880.140.770.960.820.980.760.860.840.780.760.780.740.850.880.680.970.860.960.960.850.830.70.310.93
0.950.050.90.870.920.850.890.940.890.70.870.650.860.850.960.470.880.890.890.870.780.770.810.640.86
0.99-0.040.950.880.980.880.940.990.960.690.940.630.940.880.960.470.910.980.930.940.840.780.910.690.93
0.490.660.320.740.380.720.250.470.470.850.230.770.20.680.470.470.650.370.590.530.710.710.130.00.45
0.920.150.820.980.850.980.80.910.880.770.80.70.780.970.880.910.650.860.980.970.870.890.740.340.93
0.97-0.180.930.820.960.850.930.960.950.610.960.590.960.860.890.980.370.860.910.930.790.70.940.710.95
0.950.070.870.970.90.970.850.940.920.780.860.660.850.960.890.930.590.980.910.980.90.850.810.430.96
0.95-0.050.890.930.910.950.890.930.920.690.890.620.880.960.870.940.530.970.930.980.860.820.850.450.99
0.870.340.790.890.840.890.730.870.910.860.730.670.750.850.780.840.710.870.790.90.860.890.70.420.82
0.810.450.770.880.740.850.680.820.830.710.660.580.650.830.770.780.710.890.70.850.820.890.580.30.73
0.91-0.350.920.660.940.690.940.90.920.430.970.350.990.70.810.910.130.740.940.810.850.70.580.760.89
0.68-0.280.740.30.70.310.740.690.680.240.750.220.760.310.640.690.00.340.710.430.450.420.30.760.49
0.94-0.160.880.890.920.920.890.920.910.670.910.610.90.930.860.930.450.930.950.960.990.820.730.890.49
Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Jafron Biomedical fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.5B3.2B4.8B5.4B5.5B5.8B
Other Current Liab131.8M140.8M129.3M5.5M4.9M4.6M
Total Current Liabilities262.6M330.8M386.3M717.2M829.4M870.9M
Total Stockholder Equity2.1B2.8B3.4B3.6B3.1B1.8B
Other Liab51.1M61.5M52.2M125.8M144.7M151.9M
Retained Earnings1.2B1.7B2.3B2.1B2.0B1.0B
Accounts Payable32.8M50.2M60.8M128.5M135.6M142.4M
Cash1.3B1.6B2.3B2.6B2.8B3.0B
Other Assets107.9M102.4M91.6M225.4M259.2M272.2M
Net Receivables169.8M167.4M314.4M221.7M74.9M118.9M
Inventory92.3M120.7M196.5M349.1M385.0M404.2M
Other Current Assets25.9M65.3M75.3M35.6M17.3M26.1M
Total Liab324.1M383.1M1.4B1.8B2.4B2.5B
Intangible Assets48.1M89.9M101.3M100.4M100.4M53.5M
Common Stock417.3M418.7M799.1M805.5M926.3M972.6M
Property Plant Equipment457.6M639.6M905.5M1.3B1.5B1.5B
Net Tangible Assets1.6B2.1B2.7B3.2B3.7B2.0B
Deferred Long Term Liab3.4M14.8M20.4M36.0M41.3M43.4M
Total Current Assets1.6B2.0B3.1B3.3B3.3B2.1B
Non Current Assets Total934.9M1.2B1.8B2.1B2.2B1.3B
Non Currrent Assets Other77.5M58.2M162.8M148.2M107.0M102.3M
Non Current Liabilities Total61.5M52.2M1.0B1.1B1.6B1.6B
Common Stock Shares Outstanding795.5M799.1M805.5M807.7M807.6M880.0M
Net Invested Capital2.1B2.8B4.3B4.8B4.8B3.4B
Net Working Capital1.3B1.7B2.7B2.6B2.5B2.0B
Capital Stock418.7M799.1M805.5M807.7M807.6M743.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Balance Sheet is a snapshot of the financial position of Jafron Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Jafron Biomedical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jafron Biomedical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jafron currently owns. An asset can also be divided into two categories, current and non-current.